Analyst picks & changes

Amgen Inc.


Genetics Institute Inc.


Genzyme Corp.


Immunex Corp.


An FDA advisory panel decision last week not to recommend approval of IMNX's


GM-CSF for the broad indication of chemotherapy-induced neutropenia (see BioCentury Extra, April 11) spurred a spate of comments on the consequences for several companies.

Joyce Lonergan of Cowen & Co. said she expects IMNX shares to be under significant

Read the full 676 word article

How to gain access

Continue reading with a
two-week free trial.